Alex R. Rinehart

Statistics

Publications

Citations

3.7K

H-Index

Active since

1991

Affiliations

National Institute of Allergy and Infectious Diseases(Current)

Johns Hopkins University

Fred Hutch Cancer Center

University of North Carolina at Chapel Hill

Family Health International 360

Alex R. Rinehart is an author at National Institute of Allergy and Infectious Diseases specializing in antiretroviral therapy, antiviral therapy, and pharmacotherapy.

Publications per year

1991–2025

Publications

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

Raphael J. Landovitz, Deborah Donnell, Meredith E. Clement et al. · New England Journal of Medicine · 2021 · 853 citations · Full text

Public Health, Infectious Diseases, Pharmacotherapy +16

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial

Sinéad Delany‐Moretlwe, James P. Hughes, Peter Bock et al. · The Lancet · 2022 · 540 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial

Martin Markowitz, Ian Frank, Robert M. Grant et al. · The Lancet HIV · 2017 · 217 citations

Pharmacy, Pharmacology, Pharmacotherapy +11

A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy

Calvin Cohen, Susan C. Hunt, Michael Sension et al. · AIDS · 2002 · 197 citations

Life Sciences, Pharmacotherapy, Hiv Control +16

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial

Raphael J. Landovitz, Sue Li, Beatriz Grinsztejn et al. · PLoS Medicine · 2018 · 172 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

1–5 of 42